


AUGUST 2025



REVOLUTIONISING DIABETES WITH TRIGLYTZA®

Commencing Phase II - Type 2 diabetes
Preclinical - Type 1 diabetes
Preclinical - Type 2 diet induced obesity



IMPORTANT NOTICE AND DISCLAIMER

IMPORTANT: You must read the following before continuing. In accessing this document, you agree to be bound by the following terms and conditions.

This presentation has been prepared by Myopharm Limited to provide readers with background information to obtain a general understanding of the Company's plans and objectives in the context of its proposed commercial activities. This presentation is not and should not be considered as an offer or invitation to apply for or purchase any securities in the Company.

This presentation is presented to those persons who qualify as sophisticated investors (as defined in section 708(8-10) of the Act), professional investors (as defined in section 708(11) of the Act), investors to whom personal offers are made under section 708(1), or investors to whom disclosure is otherwise not required under Part 6D of the Act (collectively, "Qualified Investors").

No agreement to subscribe for the securities of the Company will be entered into on the basis of this presentation. This presentation is not a prospectus or other disclosure document under the Corporations Act and does not contain all of the information a prospective investor may reasonably require making an investment decision. This presentation contains summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. This presentation is not financial product advice. The Company is not licensed to give and does not provide financial advice. Readers must not rely on this presentation but make their own independent assessment and seek and rely upon their own independent taxation, legal, financial or other professional advice. No representation or warranty, express or implied, is given as to the fairness, accuracy, completeness, correctness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement contained in this presentation (any of which may change without notice), or the likelihood of achievement or reasonableness of forward-looking or prospective statements (if any) contained in the presentation.

Forward-looking or prospective statements (which may be identified by words such as 'may', 'could', 'believes', 'estimates', 'anticipated', 'targets', 'expects', or 'intends' and other similar words) are by their nature subject to significant uncertainties, risks and contingencies. The forward-looking or prospective statements in this presentation have been based on current expectations about future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from the expectations described. In particular, the Company notes that we are at an early stage of development, and we are yet to complete the development of the proposed plan across which its business is proposed to be operated.

While the Company considers that the expectations and plans reflected in this presentation are reasonable on the basis of the experience of the key management personnel of the Company, independent third-party information and the work done to date, neither the Company nor any other person gives any representation, assurance or guarantee that the occurrence of the events or IPO timelines expressed or implied in any forward-looking statements in this presentation will actually occur and you are cautioned not to place undue reliance on those forward-looking statements.

To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, partners, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

INVESTMENT HIGHLIGHTS



Robust pipeline

TriGlytza® lead program, RK-01, is first in a pipeline of clinical stage drug indications

Substantial growth even in an Ozempic world

Diabetes drug market projected to grow to US\$157.9 billion by 2033 Allied Research

High track record of safety

Repurposed pre-approved drugs used by millions of patients over 30 years

Baseline of revenue generation

Revenue generating, patented OMNI-D® food product business generating royalty revenues

Addressing massive unmet need

US\$412.9B estimated cost of diabetes and its complications in the US 2022 American Diabetes Association (ADA)

Innovation

Novel beta cell - centric dual combination therapy strikes at the core of Type 2 diabetes


Strong IP Position

36 patents in key end markets for OMNI-D® and supporting TriGlytza® FDA-approved IND

Seasoned leadership

Highly experienced team and advisors with biotech track record in the USA and Australia

TRIGLYTZA® - MULTI-TARGETED MOA




Improvements in Glycemic Control %HbA1c
Increased insulin sensitivity.
Prevention of Beta-cell deterioration.

TriGlytza® in mice significantly reduces %HbA1c the primary endpoint for registration of diabetes drugs by 1 unit better than Metformin, first line drug

And maintains body weight like Metformin




SIGNIFICANT DEVELOPMENT TO DATE





ANTICIPATED KEY MILESTONES FOR 2025





EXPERIENCED BOARD OF DIRECTORS



Karinza Phoenix

MBA, GAICD
Executive Chair and CEO

21 years of experience in the pharmaceutical, veterinary and capital markets sectors. Including operational and marketing roles at Pfizer, Novartis and Zoetis.

A successful track record of product development, registration and marketing launches, including commercialisation of numerous market leading blockbuster medicines.

Completed the Pfizer Inc, one-year internal leadership program in 2012.



Dr Milton Grannatt

PhD
Founding Non-Executive Director

35 years in global pharmaceuticals

Previously Vice President of Finance, Sterling Winthrop and Vice President of Global Business Development and Licensing at Novartis.

Non-Executive Director of SymBio Pharmaceuticals Limited, Tokyo.

Advisor to a number of biotechnology start ups.



Tsutomu Abe

LLB
Non-Executive Director

Over 30 years of extensive international General Counsel experience in intellectual property management and business development across many business sectors, including in biotechnology corporations.

He is currently Chief Operating Officer at TAK-Circulator Corporation, CLO at Nonpi Inc and CEO at Askleon Co. Ltd.

Previously holding roles including General Counsel at Fast Retailing Co., Ltd and Kokuyo Co., Ltd and as Corporate Officer in charge of Global Business Development and Global Alliance Management at SymBio Pharmaceuticals Limited.



Dr Trevor Lockett

PhD, MAICD
Non-Executive Director

A molecular biologist by training and a distinguished scientific career with CSIRO, in the latter years leading the Personalised Health Group. Here he directed research supporting the development of new diagnostic tests for the early detection of colorectal cancer and diet and lifestyle approaches to promoting gastrointestinal health. In 2017 he joined Rhythm Biosciences as the company's founding Managing Director, contributing to the successful ASX listing of the company in December 2017. He served as a member of Rhythm's Board from its inception in 2027, first as Executive Director, then as Non-Executive Director, retiring from the Board in November 2024. He was part time Technical Director at Rhythm from July 2020 to December 2023 and continues to consult to the company. He formerly served as a Non-Executive Director of the board of Juno Healthcare.

An Inventor of of 10 patent families and published over 100 peer reviewed publications.



STRUCTURE AND FUNDING


Capital Structure:

Shares on issue (ASIC)	58,899,266M
Share price	\$0.25 per share
Market cap post raise	\$17.8M
Unlisted options:	\$4M
	* various prices and exercise dates

Funding History:

Funds raised to date	\$3.8M
Last round	\$1.4M at \$0.165 per share (Aug-2024)

Upcoming round: \$3M





FURTHER INFORMATION

Myopharm Limited
Karinza Phoenix
Executive Chair & CEO

m: +61 498 505 321

e: kphoenix@myopharm.com

w: www.myopharm.com